JAMA Dermatology

<jats:sec><jats:title>Importance</jats:title><jats:p>There has been increased interest in low-dose oral minoxidil for androgenetic alopecia (AGA) treatment. However, the efficacy of oral minoxidil for male AGA is yet to be evaluated in comparative therapeutic trials.</jats:p></jats:sec><jats:sec><jats:title>Objective</jats:title><jats:p>To compare the efficacy, safety, and tolerability of daily oral minoxidil, 5 mg, vs twice-daily topical minoxidil, 5%, for 24 weeks in the treatment of male AGA.</jats:p></jats:sec><jats:sec><jats:title>Design, Setting, and Participants</jats:title><jats:p>This double-blind, placebo-controlled randomized clinical trial was conducted at a single specialized clinic in Brazil. Eligible men with AGA aged 18 to 55 years classified using the Norwood-Hamilton scale as 3V, 4V, or 5V were included and randomized. Data were collected from January to December 2021, and data were analyzed from September 2022 to February 2023.</jats:p></jats:sec><jats:sec><jats:title>Interventions</jats:title><jats:p>Participants were randomized 1:1 into 2 groups: oral minoxidil, 5 mg, daily and topical placebo solution; or 1 mL of topical minoxidil, 5%, twice daily and oral placebo for 24 weeks.</jats:p></jats:sec><jats:sec><jats:title>Main Outcomes and Measures</jats:title><jats:p>The primary outcome was change in terminal hair density on the frontal and vertex regions of the scalp. The secondary outcomes were change in total hair density and photographic evaluation.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Among 90 enrolled participants, 68 completed the study; of these, the mean (SD) age was 36.6 (7.8) years. A total of 33 participants were enrolled in the oral minoxidil group and 35 in the topical treatment group. Both groups were homogenous in terms of demographic data and AGA severity. For the frontal area, the mean change from baseline to week 24 between groups was 3.1 hairs per cm<jats:sup>2</jats:sup> (95% CI, −18.2 to 21.5; <jats:italic>P</jats:italic> = .27) for terminal hair density and 2.6 hairs per cm<jats:sup>2</jats:sup> (95% CI, −10.3 to 15.8; <jats:italic>P</jats:italic> = .32) for total hair density. For the vertex area, the mean change from baseline to week 24 was 23.4 hairs per cm<jats:sup>2</jats:sup> (95% CI, −0.3 to 43.0; <jats:italic>P</jats:italic> = .09) for terminal density and 5.5 hairs per cm<jats:sup>2</jats:sup> (95% CI, −12.5 to 23.5; <jats:italic>P</jats:italic> = .32) for total hair density. According to the photographic analysis, oral minoxidil was superior to topical minoxidil on the vertex (24%; 95% CI, 0 to 48; <jats:italic>P</jats:italic> = .04) but not on the frontal scalp (12%; 95% CI, −12 to 36; <jats:italic>P</jats:italic> = .24). The most common adverse effects in the oral minoxidil group were hypertrichosis (22 of 45 [49%]) and headache (6 of 45 [14%]).</jats:p></jats:sec><jats:sec><jats:title>Conclusions and Relevance</jats:title><jats:p>In this study, oral minoxidil, 5 mg, once per day for 24 weeks did not demonstrate superiority over topical minoxidil, 5%, twice per day in men with AGA.</jats:p></jats:sec><jats:sec><jats:title>Trial Registration</jats:title><jats:p>Brazilian Registry of Clinical Trials Identifier: <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://ensaiosclinicos.gov.br/rg/RBR-252w9r">RBR-252w9r</jats:ext-link></jats:p></jats:sec>

Prevalence of male and female pattern hair loss in Maryborough.

J Investig Dermatol Symp Proc

Female pattern hair loss: a clinical and pathophysiological review.

An Bras Dermatol

The psychosocial consequences of androgenetic alopecia: a review of the research literature.

Br J Dermatol

Relative efficacy of minoxidil and the 5-a reductase inhibitors in androgenetic alopecia treatment of male patients: a network meta-analysis.

JAMA Dermatol

Post-finasteride syndrome.

Is topical minoxidil solution effective on androgenetic alopecia in routine daily practice?

J Dermatolog Treat

Oral minoxidil for hair loss: update and perspectives.

Hair Transplant Forum Int

Classification of male-pattern hair loss.

Int J Trichology

Estimating sample sizes for repeated measurement designs.

Control Clin Trials

Follicular map: a novel approach to quantitative trichoscopy.

Skin Appendage Disord

Efficiency of hair detection in hair-to-hair matched trichoscopy.

A randomized, double-blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the correction of nasolabial folds.

Dermatol Surg

Anomalous values and missing data in clinical and experimental studies.

J Vasc Bras

Assessing normality of data in clinical and experimental trials.

Analysis of longitudinal data from animals with missing values using SPSS.

Nat Protoc

P value and effect-size in clinical and experimental studies.

Reversal of baldness in patient receiving minoxidil for hypertension.

N Engl J Med

Efficacy and safety of oral minoxidil 5 mg once daily in the treatment of male patients with androgenetic alopecia: an open-label and global photographic assessment.

Dermatol Ther (Heidelb)

Post—COVID-19 hair loss: prevalence and associated factors among 5,891 patients.

Int J Dermatol

Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: a randomized clinical trial.

J Am Acad Dermatol

Prospective cardiovascular evaluation with 24-hour Holter and 24-hour ambulatory blood pressure monitoring in men using 5-mg oral minoxidil for androgenetic alopecia.

Adverse effects of low-dose oral minoxidil for androgenetic alopecia in 435 patients.

Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients.

A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women.

There has been increased interest in low-dose oral minoxidil for androgenetic alopecia (AGA) treatment. However, the efficacy of oral minoxidil for male AGA is yet to be evaluated in comparative therapeutic trials.
To compare the efficacy, safety, and tolerability of daily oral minoxidil, 5 mg, vs twice-daily topical minoxidil, 5%, for 24 weeks in the treatment of male AGA.
This double-blind, placebo-controlled randomized clinical trial was conducted at a single specialized clinic in Brazil. Eligible men with AGA aged 18 to 55 years classified using the Norwood-Hamilton scale as 3V, 4V, or 5V were included and randomized. Data were collected from January to December 2021, and data were analyzed from September 2022 to February 2023.
Participants were randomized 1:1 into 2 groups: oral minoxidil, 5 mg, daily and topical placebo solution; or 1 mL of topical minoxidil, 5%, twice daily and oral placebo for 24 weeks.
The primary outcome was change in terminal hair density on the frontal and vertex regions of the scalp. The secondary outcomes were change in total hair density and photographic evaluation.
Among 90 enrolled participants, 68 completed the study; of these, the mean (SD) age was 36.6 (7.8) years. A total of 33 participants were enrolled in the oral minoxidil group and 35 in the topical treatment group. Both groups were homogenous in terms of demographic data and AGA severity. For the frontal area, the mean change from baseline to week 24 between groups was 3.1 hairs per cm2 (95% CI, -18.2 to 21.5; P = .27) for terminal hair density and 2.6 hairs per cm2 (95% CI, -10.3 to 15.8; P = .32) for total hair density. For the vertex area, the mean change from baseline to week 24 was 23.4 hairs per cm2 (95% CI, -0.3 to 43.0; P = .09) for terminal density and 5.5 hairs per cm2 (95% CI, -12.5 to 23.5; P = .32) for total hair density. According to the photographic analysis, oral minoxidil was superior to topical minoxidil on the vertex (24%; 95% CI, 0 to 48; P = .04) but not on the frontal scalp (12%; 95% CI, -12 to 36; P = .24). The most common adverse effects in the oral minoxidil group were hypertrichosis (22 of 45 [49%]) and headache (6 of 45 [14%]).
In this study, oral minoxidil, 5 mg, once per day for 24 weeks did not demonstrate superiority over topical minoxidil, 5%, twice per day in men with AGA.
Brazilian Registry of Clinical Trials Identifier: RBR-252w9r.

Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial.

Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia

Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia

Clinical Summary

What was studied

Key findings

Study limitations

Clinical implications

Related Questions